Cargando…
Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control
BACKGROUND: The degree of glycemic control in patients with type 2 diabetes mellitus (T2DM) may alter lipid levels and may alter the efficacy of lipid-modifying agents. OBJECTIVE: Evaluate the lipid-modifying efficacy of extended-release niacin/laropiprant (ERN/LRPT) in subgroups of patients with T2...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348131/ https://www.ncbi.nlm.nih.gov/pubmed/25750540 http://dx.doi.org/10.2147/VHRM.S70907 |
_version_ | 1782359892877639680 |
---|---|
author | Bays, Harold E Brinton, Eliot A Triscari, Joseph Chen, Erluo Maccubbin, Darbie MacLean, Alexandra A Gibson, Kendra L Ruck, Rae Ann Johnson-Levonas, Amy O O’Neill, Edward A Mitchel, Yale B |
author_facet | Bays, Harold E Brinton, Eliot A Triscari, Joseph Chen, Erluo Maccubbin, Darbie MacLean, Alexandra A Gibson, Kendra L Ruck, Rae Ann Johnson-Levonas, Amy O O’Neill, Edward A Mitchel, Yale B |
author_sort | Bays, Harold E |
collection | PubMed |
description | BACKGROUND: The degree of glycemic control in patients with type 2 diabetes mellitus (T2DM) may alter lipid levels and may alter the efficacy of lipid-modifying agents. OBJECTIVE: Evaluate the lipid-modifying efficacy of extended-release niacin/laropiprant (ERN/LRPT) in subgroups of patients with T2DM with better or poorer glycemic control. METHODS: Post hoc analysis of clinical trial data from patients with T2DM who were randomized 4:3 to double-blind ERN/LRPT or placebo (n=796), examining the lipid-modifying effects of ERN/LRPT in patients with glycosylated hemoglobin or fasting plasma glucose levels above and below median baseline levels. RESULTS: At Week 12 of treatment, ERN/LRPT significantly improved low-density lipoprotein cholesterol, high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol, triglycerides, and lipoprotein (a), compared with placebo, with equal efficacy in patients above or below median baseline glycemic control. Compared with placebo, over 36 weeks of treatment more patients treated with ERN/LRPT had worsening of their diabetes and required intensification of antihyperglycemic medication, irrespective of baseline glycemic control. Incidences of other adverse experiences were generally low in all treatment groups. CONCLUSION: The lipid-modifying effects of ERN/LRPT are independent of the degree of baseline glycemic control in patients with T2DM (NCT00485758). |
format | Online Article Text |
id | pubmed-4348131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43481312015-03-06 Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control Bays, Harold E Brinton, Eliot A Triscari, Joseph Chen, Erluo Maccubbin, Darbie MacLean, Alexandra A Gibson, Kendra L Ruck, Rae Ann Johnson-Levonas, Amy O O’Neill, Edward A Mitchel, Yale B Vasc Health Risk Manag Original Research BACKGROUND: The degree of glycemic control in patients with type 2 diabetes mellitus (T2DM) may alter lipid levels and may alter the efficacy of lipid-modifying agents. OBJECTIVE: Evaluate the lipid-modifying efficacy of extended-release niacin/laropiprant (ERN/LRPT) in subgroups of patients with T2DM with better or poorer glycemic control. METHODS: Post hoc analysis of clinical trial data from patients with T2DM who were randomized 4:3 to double-blind ERN/LRPT or placebo (n=796), examining the lipid-modifying effects of ERN/LRPT in patients with glycosylated hemoglobin or fasting plasma glucose levels above and below median baseline levels. RESULTS: At Week 12 of treatment, ERN/LRPT significantly improved low-density lipoprotein cholesterol, high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol, triglycerides, and lipoprotein (a), compared with placebo, with equal efficacy in patients above or below median baseline glycemic control. Compared with placebo, over 36 weeks of treatment more patients treated with ERN/LRPT had worsening of their diabetes and required intensification of antihyperglycemic medication, irrespective of baseline glycemic control. Incidences of other adverse experiences were generally low in all treatment groups. CONCLUSION: The lipid-modifying effects of ERN/LRPT are independent of the degree of baseline glycemic control in patients with T2DM (NCT00485758). Dove Medical Press 2015-02-24 /pmc/articles/PMC4348131/ /pubmed/25750540 http://dx.doi.org/10.2147/VHRM.S70907 Text en © 2015 Bays et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Bays, Harold E Brinton, Eliot A Triscari, Joseph Chen, Erluo Maccubbin, Darbie MacLean, Alexandra A Gibson, Kendra L Ruck, Rae Ann Johnson-Levonas, Amy O O’Neill, Edward A Mitchel, Yale B Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control |
title | Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control |
title_full | Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control |
title_fullStr | Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control |
title_full_unstemmed | Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control |
title_short | Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control |
title_sort | extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348131/ https://www.ncbi.nlm.nih.gov/pubmed/25750540 http://dx.doi.org/10.2147/VHRM.S70907 |
work_keys_str_mv | AT baysharolde extendedreleaseniacinlaropiprantsignificantlyimproveslipidlevelsintype2diabetesmellitusirrespectiveofbaselineglycemiccontrol AT brintoneliota extendedreleaseniacinlaropiprantsignificantlyimproveslipidlevelsintype2diabetesmellitusirrespectiveofbaselineglycemiccontrol AT triscarijoseph extendedreleaseniacinlaropiprantsignificantlyimproveslipidlevelsintype2diabetesmellitusirrespectiveofbaselineglycemiccontrol AT chenerluo extendedreleaseniacinlaropiprantsignificantlyimproveslipidlevelsintype2diabetesmellitusirrespectiveofbaselineglycemiccontrol AT maccubbindarbie extendedreleaseniacinlaropiprantsignificantlyimproveslipidlevelsintype2diabetesmellitusirrespectiveofbaselineglycemiccontrol AT macleanalexandraa extendedreleaseniacinlaropiprantsignificantlyimproveslipidlevelsintype2diabetesmellitusirrespectiveofbaselineglycemiccontrol AT gibsonkendral extendedreleaseniacinlaropiprantsignificantlyimproveslipidlevelsintype2diabetesmellitusirrespectiveofbaselineglycemiccontrol AT ruckraeann extendedreleaseniacinlaropiprantsignificantlyimproveslipidlevelsintype2diabetesmellitusirrespectiveofbaselineglycemiccontrol AT johnsonlevonasamyo extendedreleaseniacinlaropiprantsignificantlyimproveslipidlevelsintype2diabetesmellitusirrespectiveofbaselineglycemiccontrol AT oneilledwarda extendedreleaseniacinlaropiprantsignificantlyimproveslipidlevelsintype2diabetesmellitusirrespectiveofbaselineglycemiccontrol AT mitchelyaleb extendedreleaseniacinlaropiprantsignificantlyimproveslipidlevelsintype2diabetesmellitusirrespectiveofbaselineglycemiccontrol |